Pfizer has announced data from the Phase III trial of TALZENNA plus XTANDI in patients with metastatic castration-resistant ...
Pfizer announces positive results from phase 3 TALAPRO-2 trial of Talzenna in combination with Xtandi in patients with mCRPC: New York Friday, October 11, 2024, 09:00 Hrs [IST] Pf ...
Pfizer Inc. (NYSE: PFE) today announced positive topline results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of ...
According to findings from the TALAPRO-2 study, the combination led to significant and meaningful improvements in overall ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback